Related Experiment Video

Updated: May 7, 2026

Correlative Light and Electron Microscopy to Study Microglial Interactions with β-Amyloid Plaques
10:52

Correlative Light and Electron Microscopy to Study Microglial Interactions with β-Amyloid Plaques

Published on: June 1, 2016

Synthesis of methoxy-X04 derivatives and their evaluation in Alzheimer's disease pathology

Alexander Boländer1, Daniel Kieser, Christoph Scholz

  • 1Clemens Schöpf-Institute of Organic Chemistry and Biochemistry, Technische Universität Darmstadt, Darmstadt, Germany.

Neuro-Degenerative Diseases
|October 2, 2013
PubMed
Abstract

Insights

Researchers developed new methoxy-X04 derivatives to improve Alzheimer's disease (AD) diagnosis. These novel compounds show enhanced binding affinity for key AD protein aggregates, potentially leading to better imaging agents.

Area of Science:

  • Neuroscience
  • Chemical Biology
  • Medical Imaging

Background:

  • Alzheimer's disease (AD) is marked by amyloid-β plaques and tau tangles.
  • Current diagnostic methods lack sensitivity and specificity for visualizing AD pathology.
  • Methoxy-X04 is a known plaque and tangle stain but has slow in vivo clearance.

Purpose of the Study:

  • To synthesize and evaluate novel methoxy-X04 derivatives as potential imaging agents for AD.
  • To address the limitations of existing diagnostic markers for Alzheimer's disease.

Main Methods:

  • Improved synthesis of methoxy-X04 and its derivatives.
  • Affinity determination using immunohistology.
  • Displacement assays to assess target binding.

Main Results:

  • Successfully synthesized new methoxy-X04 derivatives.
  • Demonstrated varying affinities of derivatives for protein targets.
  • Identified derivatives with enhanced binding affinity compared to the parent compound.

Conclusions:

  • The new methoxy-X04 derivatives show promise as improved imaging agents for Alzheimer's disease.
  • Enhanced binding affinity may lead to more sensitive and specific diagnostic tools for AD pathology.

More Related Videos

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices04:41

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices

Published on: July 14, 2010

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein08:27

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein

Published on: July 29, 2018

Related Concept Videos

Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...